autologous cultured chondrocytes on porcine collagen membrane
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Articular Cartilage Defect
Conditions
Articular Cartilage Defect
Trial Timeline
Jul 1, 2008 → Mar 1, 2012
NCT ID
NCT00719576About autologous cultured chondrocytes on porcine collagen membrane
autologous cultured chondrocytes on porcine collagen membrane is a phase 3 stage product being developed by Vericel for Articular Cartilage Defect. The current trial status is completed. This product is registered under clinical trial identifier NCT00719576. Target conditions include Articular Cartilage Defect.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06915233 | Phase 3 | Recruiting |
| NCT01251588 | Pre-clinical | Completed |
| NCT00719576 | Phase 3 | Completed |
Competing Products
6 competing products in Articular Cartilage Defect
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| Abatacept | Bristol Myers Squibb | Phase 3 | 76 |
| Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP) | UCB | Phase 3 | 74 |
| autologous cultured chondrocytes on porcine collagen membrane | Vericel | Pre-clinical | 18 |
| Carticel (autologous cultured chondrocyte) implantation | Vericel | Pre-clinical | 18 |
| Carticel (autologous cultured chondrocyte) implantation | Vericel | Approved | 80 |